Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Antibody-drug conjugate (CD79b/MMAE)
Polatuzumab vedotin
Polivy · Pola
A CD79b/MMAE conjugate for DLBCL — renal risk is mainly tumor lysis, with little direct nephrotoxicity reported.
MildAntibody-drug conjugate · approved 2019
Diffuse large B-cell lymphoma
Signature kidney injury
Prerenal / Hemodynamic AKI
Renal data are limited; direct nephrotoxicity is not a prominent trial signal. AKI is case-level and chiefly tumor-lysis- or volume-mediated. Renal-specific incidence is not quantified.
Source: Tilly et al., N Engl J Med 2021 (POLARIX)
Mechanism of kidney injury
Indirect: rapid B-cell lysis in bulky DLBCL can cause tumor lysis with crystal nephropathy and electrolyte derangement; cytopenias, peripheral neuropathy and GI toxicity dominate the direct profile. MMAE-related tubular toxicity is not a notable clinical signal at approved doses.
Clinical presentation
Tumor-lysis labs (hyperuricemia, hyperphosphatemia, hyperkalemia, hypocalcemia) and creatinine rise in bulky disease; otherwise renal function usually preserved.
Onset
Early — tumor lysis during initial cycles of bulky disease.
Reversibility
Reversible
Anticancer mechanism
Antibody-drug conjugate targeting CD79b (a B-cell receptor component) and delivering MMAE via a protease-cleavable linker. Approved for diffuse large B-cell lymphoma (with rituximab/bendamustine in relapsed disease, and frontline with R-CHP).
Management
Tumor-lysis management (hydration, urate-lowering therapy, electrolyte correction); supportive AKI care.
Risk factors
- High/bulky tumor burden
- Rapidly proliferative lymphoma
- Volume depletion
- Pre-existing CKD
Prevention
- Tumor lysis prophylaxis in high-risk patients
- Hydration
- Monitor electrolytes and renal function during early cycles
Note · Emerging renal data; the principal renal risk is tumor lysis rather than direct tubular toxicity.
Clinical depth
Renal dose adjustment
No starting-dose adjustment for CrCl >=30; data are insufficient below CrCl 30. MMAE is hepatically (CYP3A4) metabolized rather than renally cleared.
Dialyzability & ESKD dosing
Not appreciably dialyzed (large ADC; protein-bound MMAE). No supplemental dosing guidance for HD/PD.
Differential diagnosis
Tumor lysis AKI versus prerenal AKI from intercurrent illness; intrinsic MMAE tubular injury is not an expected mechanism.
Monitoring
- Tumor lysis labs during initial cycles of bulky disease
- CBC and neurologic exam (cytopenias, neuropathy)
- Serum creatinine each cycle
Key trials & series
- POLARIX (Tilly NEJM 2021, frontline DLBCL with R-CHP)
- GO29365 (Sehn JCO 2019, R/R DLBCL)
Clinical pearls
- As with other MMAE ADCs in lymphoma, the renal risk tracks tumor burden (tumor lysis), not the payload.
- Neuropathy and cytopenias drive dose decisions; the kidney is rarely the limiting organ.
- Limited data below CrCl 30 - extrapolate cautiously.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of antibody-drug conjugate (cd79b/mmae)s.
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression (payload-dependent)
Ophthalmic
Keratopathy, uveitis, retinopathy
- Keratopathy (belantamab, mirvetuximab, tisotumab)
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Interstitial lung disease (deruxtecan ADCs)
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Peripheral neuropathy (MMAE payloads)
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkPolatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.Tilly H et al. · N Engl J Med 2021 · PMID 34904799POLARIX frontline phase III; characterizes the safety profile of polatuzumab vedotin with R-CHP.PMIDPolatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Sehn LH et al. · J Clin Oncol 2019 · PMID 31693429Registrational randomized trial defining the toxicity profile (cytopenias, neuropathy).PMIDTumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.Howard SC et al. · Ann Hematol 2016 · PMID 26758269TLS risk across novel hematologic agents, framing the indirect renal risk.PMIDAntibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know.Markides DM et al. · Ann Emerg Med 2024 · PMID 39641680Class review of ADC toxicities and acute presentations.
Related agents
Other agents sharing the same signature kidney injury.